Lenzetto (Estradiol Hemihydrate)

Estradiol in Lenzetto binds to estrogen receptors ERα and ERβ throughout the body. This receptor activation regulates the transcription of estrogen‑responsive genes, restoring normal estrogenic activity in tissues like the brain, bone, and skin, which alleviates menopausal symptoms and supports bone health.

The specific dose and patch change interval for Lenzetto are determined by the prescribing clinician based on the individual’s clinical situation, severity of symptoms, and response to therapy. Patients should follow the prescriber’s instructions and not alter the dosing regimen on their own.

Lenzetto is contraindicated in pregnancy and breastfeeding because systemic estrogen exposure can affect fetal development and milk production. Women who are pregnant, planning to become pregnant, or nursing should discuss alternative therapies with their healthcare provider.

To order Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lenzetto delivers estradiol transdermally, providing more stable serum levels than oral estrogen, which undergoes first‑pass metabolism. This route can reduce gastrointestinal side effects and may have a lower impact on hepatic protein synthesis, making it a preferred option for many women requiring consistent estrogen replacement.

Lenzetto patches should be stored at room temperature, below 25 °C, in their original sealed packaging. Protect them from moisture, direct sunlight, and extreme temperatures. Do not apply a patch that appears damaged or expired, and keep out of reach of children.

Lenzetto is applied to clean, dry, intact skin on the lower abdomen or buttock. The patch is typically worn for a prescribed period (e.g., one week) and then replaced with a new patch at the same site or a different approved site, following the prescriber’s schedule.

Serious risks include venous thromboembolism, stroke, and gallbladder disease. Women with a history of clotting disorders, cardiovascular disease, or estrogen‑dependent cancers should be evaluated carefully before initiating therapy, and any signs of these conditions require immediate medical attention.

Lenzetto should not be used by women with active or past estrogen‑dependent malignancies, unexplained vaginal bleeding, known thromboembolic disorders, severe liver disease, or those who are pregnant or breastfeeding. Contra‑indications are determined by the prescribing clinician based on individual medical history.